We are interested in cancer vaccines of potential clinical application. In this sense, we are studying an antitumor vaccine based on a tumor-derived antigen named Ca10. This antigen is produced by the Ehrlich ascites tumor cell line. Interestingly, Ca10-vaccinated mice are highly resistant to the growth of this tumor in vivo. We are addressing the cellular and molecular mechanisms underlying this protection, as well as the expression of this antigen in different tumors. This would be of great interest as it could expand the cancer types where this vaccine could be indicated.
Comments